Skip to main content

Intradigm Licenses siRNA IP from UMass Medical School

NEW YORK (GenomeWeb News) – Intradigm has licensed siRNA technology from the University of Massachusetts Medical School that will help in its RNAi-based therapeutics programs, the company said today.
 
The UMass intellectual property covers “certain efficacy-enhancing structural elements” of siRNA, as well as parameters for structural modifications that will help the company “significantly improve the potency and efficacy of RNAi therapeutics,” Intradigm said.
 
The Palo Alto, Calif.-based company said its RNAi NPX delivery technology carries active siRNA molecules that can help improve circulation half life and selective distribution to targeted tissue.
 
The company’s multi-targeted therapeutics can silence several mRNAs representing parallel or synergistic elements of the same disease pathway, Intradigm said.
 
Financial terms of the agreement were not released.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that says the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.